ArticleArchives of toxicology2025
Predicting the developmental toxicity of 8-methyl-benzo[a]pyrene (BaP) by physiologically based kinetic (PBK) modeling-facilitated reverse dosimetry and read-across from BaP.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Position-specific methyl substitution on benzo[a]pyrene drives AHR-dependent fin duplication in zebrafish.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The present study predicts an in vivo dose-response curve for developmental toxicity of 8-methyl-benzo[a]pyrene (8-MBaP) in rats using PBK model-facilitated reverse dosimetry and read-across from a previously developed model for BaP. As for BaP, in vitro developmental toxicity of 8-MBaP in the mouse embryonic stem cell test (mEST) was shown to require bioactivation to its 3-hydroxy metabolite (3-OH-8-MBaP). To facilitate extrapolation of the in vitro observed developmental toxicity of 3-OH-8-MBaP to an in vivo dose-response curve for 8-MBaP, a PBK model for 8-MBaP was built based on the previously developed PBK model for BaP. The PBK models for BaP and 8-MBaP were validated based on (i) comparison of predicted blood concentrations of BaP or 8-MaP to blood concentrations in rats dosed with BaP or 8-MBaP in the present study and (ii) literature-reported blood concentrations of BaP and its metabolite 3-OH-BaP in rats upon dosing with BaP. The predicted half maximal effect dose (ED
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.